Therakos is the newest member of the VINSE Industry Affiliates Program! For over 35 years, Therakos has been at the forefront of immune cell therapy, pioneering the clinical use of extracorporeal photopheresis (ECP) to help patients around the world. With more than 2 million treatments delivered across 30+ countries since 1987, Therakos continues to transform what’s possible in immune system modulation. Their flagship CELLEX® Photopheresis System integrates cellular processing, photoactivation, and reinfusion—representing a powerful convergence of immunology, engineering, and clinical care.
Recently acquired by CVC Capital, Therakos is entering an exciting new phase of growth with a strong focus on collaborative mechanistic research, new product development, and innovation beyond its core in ECP. The company is currently constructing a new U.S. Innovation Center in Franklin, Tennessee, where they expect to recruit and employ 35+ engineers and scientists to complement existing teams in Dublin, Ireland. This R&D team will be focused on developing next generation technology platforms for immunomodulation and bedside immune cell therapy.
Therakos also shares a long-standing connection with Vanderbilt University Medical Center, where their ECP therapy has been a key part of immunotherapy programs for over two decades. We’re proud to welcome Therakos to the VINSE IAP and look forward to the opportunities of this partnership.